Menu
  • Home
  • About
    • About Us
    • Our Team
    • Publications
  • Platform
    • CAR-γδ T Cell
    • iPSC-γδ NKT Cell
  • Pipeline
  • Manufacturer
  • Investors
  • Contact Us
  • Shareholder Benefits
  • Make An Appointment

CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts

« Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts B2 miceta-roglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes »
cytomed
  • Email:

    enquiry@cytomed.sg

    Phone:

    +607-3824911
    +65-62507738
  • Quick Links

      • Home
      • About Us
      • Publications
      • Contact Us

    Let's Get Connected!

  • CytoMed Therapeutics Ltd (201808327H)

    Registered Office:

    1 Commonwealth #08-22 Singapore 149544

    CytoMed Therapeutics (Malaysia) Sdn Bhd (1074609-M)

    Registered Office:

    Room 503 5th Floor, Merlin Tower, Jalan Meldrum 80000 Johor Bahru, Malaysia

  • © 2021 CytoMed Therapeutics Pte Ltd

    Designed & Developed by Klizo Solutions Pvt. Ltd.